6667 Stock Overview
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing, cancer screening, and other services in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mega Genomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$9.10 |
| 52 Week High | HK$12.40 |
| 52 Week Low | HK$7.68 |
| Beta | 0 |
| 1 Month Change | 0.11% |
| 3 Month Change | -0.33% |
| 1 Year Change | -19.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.44% |
Recent News & Updates
Shareholder Returns
| 6667 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 0.6% | 6.3% | 3.5% |
| 1Y | -19.6% | -29.9% | -9.9% |
Return vs Industry: 6667 exceeded the Hong Kong Healthcare industry which returned -29.9% over the past year.
Return vs Market: 6667 underperformed the Hong Kong Market which returned -9.9% over the past year.
Price Volatility
| 6667 volatility | |
|---|---|
| 6667 Average Weekly Movement | 13.4% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 6667's share price has been volatile over the past 3 months.
Volatility Over Time: 6667's weekly volatility has increased from 8% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 229 | n/a | www.megagenomics.cn |
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing, cancer screening, and other services in China. It offers general testing services comprising brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, which include hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; andRNF180/Septin9 gastric cancer screening test, as well as executive testing services, such as personal whole genome test and whole-exome sequencing package for adults.
Mega Genomics Limited Fundamentals Summary
| 6667 fundamental statistics | |
|---|---|
| Market cap | HK$2.17b |
| Earnings (TTM) | HK$32.45m |
| Revenue (TTM) | HK$163.47m |
66.4x
P/E Ratio13.2x
P/S RatioIs 6667 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6667 income statement (TTM) | |
|---|---|
| Revenue | CN¥151.30m |
| Cost of Revenue | CN¥63.00m |
| Gross Profit | CN¥88.30m |
| Other Expenses | CN¥58.26m |
| Earnings | CN¥30.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 58.36% |
| Net Profit Margin | 19.85% |
| Debt/Equity Ratio | 3.5% |
How did 6667 perform over the long term?
See historical performance and comparison